Man Group’s Intellia Therapeutics NTLA Stock Holding History

Man Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$690K	Buy	53,795 +40,336	+300%	+$514K	﹤0.01%	1966
2025 Q4	$121K	Buy	+13,459	New	+$185K	﹤0.01%	2176
2024 Q2	–	Sell	-47,986	Closed	-$1.32M	–	2194
2024 Q1	$1.32M	Sell	47,986 -146,119	-75%	-$4.06M	﹤0.01%	1451
2023 Q4	$5.92M	Buy	+194,105	New	+$5.58M	0.02%	873
2023 Q3	–	Hold	0	–	–	–	1450
2023 Q1	–	Sell	-30,465	Closed	-$1.06M	–	2190
2022 Q4	$1.06M	Buy	30,465 +8,611	+39%	+$409K	﹤0.01%	1302
2022 Q3	$1.22M	Buy	+21,854	New	+$1.36M	0.01%	1220
2018 Q4	–	Sell	-32,400	Closed	-$927K	–	2055
2018 Q3	$927K	Sell	32,400 -65,900	-67%	-$1.92M	﹤0.01%	1694
2018 Q2	$2.69M	Sell	98,300 -43,200	-31%	-$1.05M	0.01%	1246
2018 Q1	$2.98M	Buy	+141,500	New	+$3.48M	0.01%	1113

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Man Group's NTLA Position: Q1 2026 in Review

Man Group increased its Intellia Therapeutics (NTLA) stake by 300% in Q1 2026, buying an estimated $514K and bringing the position to 53,795 shares worth $690K. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

Man Group first reported a position in NTLA in Q1 2018 and has held it in 9 quarters since. The position peaked at $5.92M in Q4 2023. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Man Group held 53,795 shares of Intellia Therapeutics worth $690K as of Q1 2026.
Man Group bought 40,336 Intellia Therapeutics shares in Q1 2026, an estimated $514K.
Intellia Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1966 holding.
Man Group first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 9 quarters since.
Man Group's Intellia Therapeutics position peaked at $5.92M in Q4 2023.
302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.